Skip to content
Search

Latest Stories

Independent economic analysis will not be published before contract announcement, says NHSE

Independent economic analysis will not be published before contract announcement, says NHSE

Pharmacy minister Stephen Kinnock


The independent economic analysis of pharmacy finances will not be published before a new funding contract has been announced despite calls for the immediate release of the review.


Last week, pharmacy minister Stephen Kinnock said the final report was “nearing completion”.

However, whilst it has been shared with both the government and Community Pharmacy England (CPE), NHS England national director for primary care Dr Amanda said there are no plans for any imminent updates.

Doyle added that NHSE had agreed with CPE “not to comment publicly on anything related to the uplift or funding arrangements for the sector given we remain in consultation”.

Last month, Health and Social Care Committee (HSCC) chair Layla Moran wrote to Doyle asking for the report to be published “immediately”.

The National Pharmacy Association (NPA) and the Independent Pharmacies Association (IPA) also wrote to NHSE, demanding the immediate release of the report that was commissioned last autumn.

An open letter, signed by the owners of 3,034 pharmacies in England, calls for transparency on the funding gap amid ongoing contract negotiations.

The associations argued that withholding this analysis conceals the true extent of the sector’s financial plight from contractors and parliamentarians.

“We believe publishing this analysis now will help Ministers, the NHS and pharmacies chart a way to securing the stable and sustainable pharmacy network that our patients so desperately need,” they wrote.

NPA Chair Nick Kaye echoed these concerns, stating that the analysis would expose “the true and devastating extent to which funding for community pharmacy falls short.”

“The hundreds of pharmacy owners signing the open letter agree with us that pharmacies, patients and the public’s representatives in parliament should be allowed to see this vital information without further delay.

“There is no justification for the public to be kept in the dark on an issue of such national significance,” he added.

Doyle said that NHSE was committed to publishing the report in full but added: “we will publish the economic analysis report with the outcome of the (pharmacy contract) consultation”.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less